ImmusanT Inc-製薬・医療分野:企業M&A・提携分析

◆英語タイトル:ImmusanT Inc - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA8014208
◆発行会社(調査会社):GlobalData
◆発行日:2017年11月22日
◆ページ数:26
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single UserUSD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
ImmusanT Inc (ImmusanT) is a drug company that discovers and develops therapies for celiac disease. The company’s pipeline products include Nexvax 2 and Nexvax 3. Its pipeline product Nexvax 2 is used for treating, preventing and diagnosing celiac disease. ImmusanT’s pipeline products are also used for the treatment of diabetes, thyroid autoimmunity, autoimmune liver diseases, rheumatoid arthritis and allergies with defined peptides such as peanut allergy. The company’s treatment for celiac disease is an immune tolerizing therapy that uses a series of peptides that target the common genetics in the disease. It also offers clinical trial services. ImmusanT is headquartered in Cambridge, Massachusetts, the US.

ImmusanT Inc – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
ImmusanT Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
ImmusanT Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
ImmusanT Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
ImmusanT Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 8
ImmusanT Inc, Medical Devices Deals, 2011 to YTD 2017 9
ImmusanT Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 10
ImmusanT Inc, Pharmaceuticals & Healthcare, Deal Details 11
Asset Purchase 11
ImmusanT Acquires A Discovery Platform From Nexpep 11
Venture Financing 12
ImmusanT Raises USD40 Million in Series C Financing 12
ImmusanT Raises USD12 Million Series B Venture Financing 13
ImmusanT Secures US$20 Million In Series A Round Of Financing 14
ImmusanT Secures Seed Financing 15
Partnerships 16
ImmusanT Enters Into Research Agreement With Walter and Eliza Hall Institute of Medical Research 16
ImmusanT Inc – Key Competitors 17
ImmusanT Inc – Key Employees 18
ImmusanT Inc – Locations And Subsidiaries 19
Head Office 19
Recent Developments 20
Product News 20
05/19/2016: ImmusanT Announces Presentations at Digestive Disease Week 2016 20
05/08/2017: ImmusanT Reports Data on Novel Celiac Disease Diagnostic Approach 22
Clinical Trials 23
May 12, 2017: ImmusanT Announces Publication of Positive Data from Phase 1 Trials of Nexvax2 in Celiac Disease Patients 23
Feb 22, 2017: ImmusanT Announces Completion of Phase 1b Clinical Trial of Nexvax2 for the Treatment of Celiac Disease 24
May 24, 2016: ImmusanT Reports Nexvax2 Phase 1 Data in Patients with Celiac Disease 25
Appendix 26
Methodology 26
About GlobalData 26
Contact Us 26
Disclaimer 26

List of Tables
ImmusanT Inc, Pharmaceuticals & Healthcare, Key Facts 2
ImmusanT Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
ImmusanT Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
ImmusanT Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
ImmusanT Inc, Deals By Therapy Area, 2011 to YTD 2017 8
ImmusanT Inc, Medical Devices Deals, 2011 to YTD 2017 9
ImmusanT Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 10
ImmusanT Acquires A Discovery Platform From Nexpep 11
ImmusanT Raises USD40 Million in Series C Financing 12
ImmusanT Raises USD12 Million Series B Venture Financing 13
ImmusanT Secures US$20 Million In Series A Round Of Financing 14
ImmusanT Secures Seed Financing 15
ImmusanT Enters Into Research Agreement With Walter and Eliza Hall Institute of Medical Research 16
ImmusanT Inc, Key Competitors 17
ImmusanT Inc, Key Employees 18

★海外企業調査レポート[ImmusanT Inc-製薬・医療分野:企業M&A・提携分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Deloitte Touche Tohmatsu Ltd:企業の戦略的SWOT分析
    Deloitte Touche Tohmatsu Ltd - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major produc …
  • Sunvault Energy Inc:電力:M&Aディール及び事業提携情報
    Summary Sunvault Energy Inc (Sunvault Energy) is a renewable energy company that provides solar energy products and solutions. The company provides products such as solar energy products, renewable energy products, water and sewer equipment, wind power generation equipment, solar power generation eq …
  • Panacea Biotec Ltd (PANACEABIO):製薬・医療:M&Aディール及び事業提携情報
    Summary Panacea Biotec Ltd (Panacea) is a research-based health management company which focuses on manufactures and commercializes pharmaceuticals; biopharmaceuticals; natural, and indigenous products; and vaccines. Its vaccines portfolio includes paediatric vaccines, including trivalent and monova …
  • Europlasma SA (ALEUP):電力:M&Aディール及び事業提携情報
    Summary Europlasma SA (Europlasma) is a leading provider of clean technology and renewable energy solutions in Europe. The company along with its group companies offers plasma solutions to treat gas and hazardous waste and conducts waste disposal and power production from waste and biomass and recyc …
  • Lycored Ltd:企業の戦略・SWOT・財務情報
    Lycored Ltd - Strategy, SWOT and Corporate Finance Report Summary Lycored Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate act …
  • Catalyst Paper Corp:企業の戦略的SWOT分析
    Catalyst Paper Corp - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and se …
  • Sygnis AG (LIO1):医療機器:M&Aディール及び事業提携情報
    Summary Sygnis AG (Sygnis), formerly Sygnis Pharma AG is a developer of novel products and tools in the field of molecular biology. The company undertakes development and marketing of new molecular biological technologies for DNA amplification and sequencing. Its offers products such as single cell …
  • Tampa Electric Co-エネルギー分野:企業M&A・提携分析
    Summary Tampa Electric Company (TEC), a subsidiary of Emera Inc., is an energy utility. It conducts the generation, purchase, transmission, distribution and sale of electricity and the distribution, purchase and sale of natural gas in Florida. The service area for electric operations covers West Cen …
  • Mitochon Pharmaceuticals Inc-製薬・医療分野:企業M&A・提携分析
    Summary Mitochon Pharmaceuticals Inc (Mitochon Pharma) is a biotechnology company that develops drugs for neurodegenerative and neuromuscular diseases. The company’s pipeline products include mitochondrial modulators such as MP-101, MP-201 and MP-301. It targets diseases such as batten disease, stro …
  • Laboratorios LETI SL:企業の戦略的SWOT分析
    Laboratorios LETI SL - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and s …
  • Silver Peak Systems Inc:企業の戦略的SWOT分析
    Silver Peak Systems Inc - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products an …
  • Novavax Inc (NVAX)-製薬・医療分野:企業M&A・提携分析
    Summary Novavax Inc (Novavax) is a clinical-stage biotechnology company that focuses on the discovery, development and commercialization of vaccines to prevent a range of infectious diseases. Its product portfolio includes recombinant nanoparticle vaccines and adjuvants. The company develops vaccine …
  • Colt’s Manufacturing Company LLC:企業の戦略的SWOT分析
    Colt's Manufacturing Company LLC - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major pr …
  • Electric Power Development Co Ltd (9513):電力:M&Aディール及び事業提携情報
    Summary Electric Power Development Co., Ltd. (J-Power) is a wholesale electric utility that supplies hydroelectric and thermal power. It owns and operates a network of hydroelectric, thermal, wind and geothermal power plants. The group provides electricity and transmission services to major electric …
  • Nanosonics Ltd (NAN)-医療機器分野:企業M&A・提携分析
    Summary Nanosonics Ltd (Nanosonics) is a medical technology company, which focuses on the development of technologies for infection control. Its product portfolio includes decontamination products and accessories for the prevention of hospital acquired infections (HAI). The company’s trophon EPR is …
  • Sunrise Coal LLC:企業の戦略・SWOT・財務分析
    Sunrise Coal LLC - Strategy, SWOT and Corporate Finance Report Summary Sunrise Coal LLC - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and cor …
  • Industrial Bank Co., Ltd.:企業の戦略・SWOT・財務分析
    Industrial Bank Co., Ltd. - Strategy, SWOT and Corporate Finance Report Summary Industrial Bank Co., Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service …
  • UBS Group AG:企業のM&A・事業提携・投資動向
    UBS Group AG - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's UBS Group AG Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), divestments, …
  • Luxshare Precision Industry Co., Ltd. (002475):企業の財務・戦略的SWOT分析
    Luxshare Precision Industry Co., Ltd. (002475) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key str …
  • Aratana Therapeutics Inc (PETX):企業の財務・戦略的SWOT分析
    Summary Aratana Therapeutics Inc (Aratana) is a provider of pet care solutions. The company develops, commercializing and markets biopharmaceutical products for medical condition in cats and dogs. Its pipeline portfolio consists of small molecule pharmaceuticals and large molecule biologics that aim …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆